Skip to search formSkip to main contentSkip to account menu

Ovarex

Known as: OvaRex Monoclonal Antibody B43.13 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

oregovomab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Oregovomab: profile report
The lifetime risk of ovarian cancer has been estimated to be 1.4% (1 in 70 women), with a 5-year survival rate for all stages of… 
Review
2006
Review
2006
Final follow up survey of the randomized Pbo-controlled study of oregovomab (Ov) as a consolidation treatment for advanced ovarian cancer (OC): Insights into surveillance approaches.
5079 Background: Ov is a monoclonal antibody specific for CA125 currently in two phase III studies as a consolidation… 
Review
2004
Review
2004
Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
Recent advances in the molecular and cellular biology of malignancy and tumour immunology have stimulated significant progress in… 
2001
2001
OvaRex (AltaRex).
  • I. Brukner
  • IDrugs : the investigational drugs journal
  • 2001
  • Corpus ID: 25800238
AltaRex is developing OvaRex (B43.13), a monoclonal antibody vaccine, for the potential treatment of ovarian cancer. Additionally… 
Highly Cited
1998
Highly Cited
1998
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)
Abstract Intravenous injection of the murine monoclonal anti-CA125 antibody B43.13 (Ovarex: Ab1) into ovarian cancer patients led… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)